All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @connercoyofficial on TikTok · 47s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @connercoyofficial's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Here's an update on my people challenge hundred dollars ten thousand dollars. This is day four. I think
  2. 0:05Started with a hundred dollars now. We're at 211 and 37 cents in four days. I think
  3. 0:12Monday about ten dollars Wednesday is really good day Thursday, and then this video is about Friday
  4. 0:1923 dollars on Friday. It was a good day
  5. 0:22Doubling my money in four days is pretty good
  6. 0:25But the goal of this is to go from a hundred dollars to ten thousand dollars in however long it takes I
  7. 0:32Think ten thousand dollars is reasonable, but it's um
  8. 0:35Far enough out to where it's an actual goal
  9. 0:38So that was for Friday. I'll make a trade today post a video do that every day track my progress and y'all see where I'm at

GLP-1 drugs and options trading: what's actually being claimed?

connercoyofficial

TikTok creator

179.4K viewsWatch on TikTok

Quick answer

This video does not involve GLP-1 medications, peptides, or any health intervention. The content is financial in nature, specifically retail options trading on Webull, and carries no clinical context relevant to telehealth or weight management. The GLP-1 category tag appears to be a misclassification.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 5 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For GLP-1 drugs and options trading: what's actually being claimed?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

GLP-1 drugs and options trading: what's actually being claimed? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "GLP-1 drugs and options trading: what's actually being claimed?" from connercoyofficial. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video does not involve GLP-1 medications, peptides, or any health intervention.

The reason this review is not generic is the source wording and the canonical claim label "glp1 good progress so far im stayinb light on the contracts ive o." In this clip, the useful excerpt is: "Here's an update on my people challenge hundred dollars ten thousand dollars." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

A $100 to $10,000 challenge requires a 9,900% return; the average annual return of the S&P 500 is roughly 10%.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

This video does not involve GLP-1 medications, peptides, or any health intervention.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This video does not involve GLP-1 medications, peptides, or any health intervention. The content is financial in nature, specifically retail options trading on Webull, and carries no clinical context relevant to telehealth or weight management. The GLP-1 category tag appears to be a misclassification.
  • Over 97% of retail day traders who persist more than 300 days lose money, per Chague, De-Losso, and Giovannetti (2020, Journal of Financial Economics).
  • A $100 to $10,000 challenge requires a 9,900% return; the average annual return of the S&P 500 is roughly 10%.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Over 97% of retail day traders who persist more than 300 days lose money, per Chague, De-Losso, and Giovannetti (2020, Journal of Financial Economics).
  • A $100 to $10,000 challenge requires a 9,900% return; the average annual return of the S&P 500 is roughly 10%.
  • Barber, Huang, Odean, and Schwarz (2021, Journal of Finance) found that more frequent trading is the primary driver of retail investor losses, not gains.
  • Options contracts can lose 100% of their value at expiration, a risk that small accounts cannot absorb the way larger diversified portfolios can.
  • Social trading visibility pushes retail traders toward riskier positions to maintain perceived performance, per Pelster and Breitmayer (2019, Journal of Banking and Finance).
  • Four days of trading data has no statistical predictive power about long-term outcomes in options markets.
  • The SEC has issued multiple warnings about retail options trading driven by social media content, citing outsized losses among viewers who copy strategies without full context.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @connercoyofficial actually say?

The creator laid out a straightforward challenge: turn $100 into $10,000 through options trading, tracked daily on TikTok. On day four, he reported his account sitting at $211.37, meaning he roughly doubled his starting capital in under a week. He framed $10,000 as "reasonable" but distant enough to be a real goal.

To be fair, he's not selling a course or promising anyone else can do this. He's documenting his own trades, staying "light on the contracts" by his own admission. The video is genuinely just a progress update. But the implicit message, that doubling money in four days is a repeatable path toward 100x returns, carries real risk when 179,000 people are watching and learning from it.

Does the finance data back this up?

Short answer: the early numbers are real, but they're not a signal. They're noise. Options trading with small accounts can produce wild short-term swings in either direction, and four days of gains tells you almost nothing about long-term viability.

Research from the North American Securities Administrators Association consistently finds that roughly 70-80% of retail options traders lose money over time. A 2021 study by Barber, Huang, Odean, and Schwarz published in the Journal of Finance examined retail trading behavior and found that individual investors systematically underperform the market, with active trading being the primary driver of losses, not gains. Going from $100 to $10,000 requires a 9,900% return. Professional hedge funds celebrate 20-30% annual returns. The math on this challenge is brutal even before accounting for the psychological pressure of filming every trade publicly.

What did he get wrong, and what did he get right?

He got the framing partly right. He acknowledged the goal is far out, which shows some awareness that this isn't a get-rich-quick scheme. He's also using small position sizes, which is genuinely good risk management practice for a beginner.

What he got wrong, or at least what the video leaves dangerously unaddressed, is survivorship framing. Doubling your money in four days sounds impressive because it is, statistically speaking, an outlier outcome. Most people who start a "$100 to $10,000" challenge blow their account before they get to day 30. A 2020 paper by Chague, De-Losso, and Giovannetti in the Journal of Financial Economics studied day traders in Brazil and found that over 97% of those who persisted for more than 300 days lost money. Options trading with a small account is even higher variance than standard day trading.

The creator also doesn't mention taxes, trading fees, or the bid-ask spread costs that eat into small account returns disproportionately.

What should you actually know?

If you're watching this and thinking about copying the strategy, here's what the research actually says. Early wins in options trading are common and statistically expected for a subset of beginners. This is sometimes called "beginner's luck" in behavioral finance, and it correlates with increased risk-taking that eventually produces larger losses.

The challenge format, trading publicly with a stated goal, adds psychological pressure that research links to worse decision-making. A 2019 study by Pelster and Breitmayer in the Journal of Banking and Finance found that social trading platforms, where performance is visible to others, pushed traders toward riskier bets to maintain perceived status.

  • Options can expire worthless, meaning you can lose 100% of what you put in on a single trade.
  • The $100 starting amount limits diversification in ways that amplify risk, not reduce it.
  • TikTok finance content is not regulated financial advice, and the SEC has specifically warned about social media influencing retail options behavior.
  • If you want to learn options trading, paper trading accounts let you practice without real money on the line.

The bottom line

This video is more honest than most finance TikTok content. The creator isn't selling anything, and he's being transparent about his position sizes. But 179,000 viewers watching someone double their money in four days will, predictably, draw the wrong lesson. The right lesson is that four days of data is not a strategy. It's a starting point, and for most people who try this, it ends badly. Follow along if you're curious, but don't confuse someone else's early luck with a repeatable system.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

connercoyofficial · TikTok creator

179.4K views on this video

Good progress so far. Im stayinb light on the contracts ive only bought one contract so far. #options #webull #money #stocks #learning #future

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about over 97% of retail day traders who persist more than?

Over 97% of retail day traders who persist more than 300 days lose money, per Chague, De-Losso, and Giovannetti (2020, Journal of Financial Economics).

What does the video say about a $100 to $10,000 challenge requires a 9,900% return; the?

A $100 to $10,000 challenge requires a 9,900% return; the average annual return of the S&P 500 is roughly 10%.

What does the video say about barber, huang, odean,?

Barber, Huang, Odean, and Schwarz (2021, Journal of Finance) found that more frequent trading is the primary driver of retail investor losses, not gains.

What does the video say about options contracts can lose 100% of their value at expiration,?

Options contracts can lose 100% of their value at expiration, a risk that small accounts cannot absorb the way larger diversified portfolios can.

What does the video say about social trading visibility pushes retail traders toward riskier positions to?

Social trading visibility pushes retail traders toward riskier positions to maintain perceived performance, per Pelster and Breitmayer (2019, Journal of Banking and Finance).

What does the video say about four days of trading data has no statistical predictive power?

Four days of trading data has no statistical predictive power about long-term outcomes in options markets.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by connercoyofficial, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.